These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35956925)

  • 1. The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2.
    Ivashchenko AA; Zagribelnyy BA; Ivanenkov YA; Ivashchenko IA; Karapetian RN; Kravchenko DV; Savchuk NP; Yakubova EV; Ivachtchenko AV
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aprotinin and Avifavir
    Ivashchenko AA; Azarova VN; Egorova AN; Karapetian RN; Kravchenko DV; Krivonos NV; Loginov VG; Poyarkov SV; Merkulova EA; Rosinkova OS; Savchuk NP; Topr MA; Simakina EN; Yakubova EV; Ivachtchenko AV
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34199134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
    Redondo-Calvo FJ; Padín JF; Muñoz-Rodríguez JR; Serrano-Oviedo L; López-Juárez P; Porras Leal ML; González Gasca FJ; Rodríguez Martínez M; Pérez Serrano R; Sánchez Cadena A; Bejarano-Ramírez N; Muñoz Hornero C; Barberá Farré JR; Domínguez-Quesada I; Sepúlveda Berrocal MA; Villegas Fernández-Infantes MD; Manrique Romo MI; Parra Comino Á; Pérez-Ortiz JM; Gómez-Romero FJ;
    Eur J Clin Invest; 2022 Jun; 52(6):e13776. PubMed ID: 35342931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin Inhibits SARS-CoV-2 Replication.
    Bojkova D; Bechtel M; McLaughlin KM; McGreig JE; Klann K; Bellinghausen C; Rohde G; Jonigk D; Braubach P; Ciesek S; Münch C; Wass MN; Michaelis M; Cinatl J
    Cells; 2020 Oct; 9(11):. PubMed ID: 33143316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19.
    Luo J; Zhang Z; Zhao S; Gao R
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drugs for influenza for 2020-2021.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):169-172. PubMed ID: 33429402
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
    Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
    Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
    J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.
    Bojkova D; Stack R; Rothenburger T; Kandler JD; Ciesek S; Wass MN; Michaelis M; Cinatl J
    J Infect; 2022 Nov; 85(5):573-607. PubMed ID: 35917841
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Basic Amino Acids and Their Derivatives on SARS-CoV-2 and Influenza-A Virus Infection.
    Melano I; Kuo LL; Lo YC; Sung PW; Tien N; Su WC
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
    Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
    Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
    Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
    J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
    Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
    Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents.
    Zarkoob H; Allué-Guardia A; Chen YC; Garcia-Vilanova A; Jung O; Coon S; Song MJ; Park JG; Oladunni F; Miller J; Tung YT; Kosik I; Schultz D; Iben J; Li T; Fu J; Porter FD; Yewdell J; Martinez-Sobrido L; Cherry S; Torrelles JB; Ferrer M; Lee EM
    Commun Biol; 2022 Aug; 5(1):810. PubMed ID: 35962146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.